Keywords: Sanofi-Aventis, TargeGen, Leukemia, Lymphoma, Hematology, Blood disorders, M&A
Sanofi-Aventis buys US cancer drug developer TargeGen in deal that could be worth $560 million
Article | 30 June 2010
French drug major Sanofi-Aventis went on another spending spree this morning - albeit relatively small - announcing that it has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
